银杏达莫联合依达拉奉治疗缺血性脑卒中的临床疗效观察  

Observation on clinical efficacy of Ginkgo biloba combined with edaravone for treatment of ischemic stroke

作　　者：高君武 陈治国[1] Gao Junwu;Chen Zhiguo(Departmen of Emergency,Chengde Central Hospial,Chengde 067000,Hebei,China)

机构地区：[1]承德市中心医院急诊科,河北承德067000

出　　处：《中国中西医结合急救杂志》2020年第5期578-581,共4页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

基　　金：河北省承德市科技研究与发展计划项目(201706a030)。

摘　　要：目的 观察银杏达莫联合依达拉奉治疗缺血性脑卒中患者的临床疗效.方法 选择承德市中心医院2017年12月至2019年6月收治的缺血性脑卒中患者160例作为研究对象,将患者按随机数字表法分为对照组和观察组,每组80例.两组均给予对症支持常规治疗;对照组静脉滴注(静滴)依达拉奉注射液治疗,每次30mg,每日2次;观察组在对照组基础上加用银杏达莫注射液每次25mL,每日2次.两组均连续治疗14d.于治疗前后检测两组患者血流动力学指标〔血小板凝集指数、纤维蛋白原(Fib)、血浆黏度、血细胞比容(HCT)〕和血清中超敏C-反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)、肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)水平;采用欧洲卒中量表(ESS)评分评价患者临床疗效,并观察不良反应发生情况.结果 两组患者治疗后血小板凝集指数、Fib、血浆黏度、HCT、hs-CRP、Hcy、TNF-α及IL-8水平均较治疗前下降,且观察组治疗后上述指标水平均明显低于对照组〔血小板凝集指数:(35.9±6.4)%比(46.1±6.3)%,Fib(g/L):2.8±0.8比3.3±1.2,血浆黏度(mPa·s):1.5±0.3比1.7±0.3,HCT:0.368±0.044比0.434±0.039,hs-CRP(mg/L):3.91±1.04比4.75±0.98,Hcy(μmol/L):17.43±4.12比20.18±4.56,TNF-α(ng/L):8.07±2.74比10.24±2.38,IL-8(ng/L):15.62±3.96比19.92±4.35,均P<0.05〕.观察组治疗后总有效率明显高于对照组〔86.25%(69/80)比68.75%(55/80),P<0.05〕,连续监测两组ESS评分发现,观察组整体下降速度快,对照组整体下降趋势较平缓,整体下降速度低于观察组.观察组和对照组不良反应发生率比较差异无统计学意义〔6.25%(5/80)比3.75%(3/80),P>0.05〕.结论 银杏达莫联合依达拉奉治疗缺血性脑卒中可明显改善患者血流动力学,降低炎症反应,疗效确切且安全可靠.Objective To observe the elinical efet of Ginkgo biloha combined with edaravone on treatment of ischemic stroke.Methods The 160 patients with ischemic stroke in Chengde Central Hospital during December 2017 to June 2019 were selected as research objects,and they were randomly divided into a control group and an observation group,with 80 cases in each group.The two groups were given routine supprtive trealment;the control group was treated.with edaravone injection by intravenous drip,30 mg/time,twice a day;on the basis of treatment in the control group.the patients in observation group were added with Cinkgo biloba injeetion,25 mL/time,twice a day.The therapeutie course of two groups lasted for 14 days.The levels of hemodynamie indexes[platelet aggregation index,fibrinogen(Fib),plasma viscosity and hematocrit(HCT)]and of hypersensitive C-reactive protein(CRP),homocysteine(Hey),tumor necrosis factor-α(TNF-α)and interleukin-8(L-8)in serum were measured before and after treatment in the two groups;the European Stroke Scale(ESS)was used to evaluate the elinical efect,and the incidence of adverse reactions was observed.Results After treatment.the levels of platelet aggregation index,Fib.plasma viscosity,HCT,hs-CRP,Hey,TNF-αand IL-8 in two grouups were significantly lower than those before treatment,and the levels of above indexes in observation group were signifcantly lower than those in control group[platelet aggregation index:(35.9±6.4)%Vs..(46.1±6.3)%,Fib(g/L):2.8±0.8 vs.3.3±1.2.plasma viscosity(mPa·s):1.5±0.3 vs.1.7±0.3,HCT:0.368±0.044 vs.0.434±0.039,hs-CRP(mg/L):3.91±1.04 vs.4.75±0.98,Hey(μmol/L):17.43±4.12 vs.20.18±4.56,TNF-α(ng/L):8.07±2.74 vs.10.24±2.38.IL-8(ng/L);15.62±3.96 vs.19.92±4.35,all P<0.05].Afer treatment,the tolual efeetive rate of observation group was significandly higher than that nf control group[86.25%(69/80)vs,68.75%(55/80),P<0.05].Continuous monitoring of ESS scores of the two groups showed that the overall decline rate of observation group was faster,the overall downward

关 键 词：缺血性脑卒中 银杏达莫 依达拉奉 

分 类 号：R74[医药卫生—神经病学与精神病学]